COMPARISON OF INITIAL ANTRETROVIRAL REGIMENS (HIV)

初始抗逆转录病毒治疗方案 (HIV) 的比较

• 批准号: 7603483
• 负责人: Ann Cornwall Collier
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603483
• 关键词: Atazanavir; Blinded; Computer Retrieval of Information on Scientific Projects Database; Daily; Enrollment; Funding; Grant; HIV Infections; Institution; Label; Lamivudine; Metabolic; Nucleosides; Phase; Randomized; Research; Research Personnel; Resources; Reverse Transcriptase Inhibitors; Ritonavir; Safety; Scanning; Source; Tenofovir; Treatment Protocols; United States National Institutes of Health; Upper arm; Week; abacavir; efavirenz; emtricitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase IIIB, multicenter, randomized, four-arm study of initial therapy for HIV infection. It will compare the efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced atazanavir (ATV) to efavirenz (EFV) (in combination with either daily emtricitabine [FTC]/tenofovir [TDF] or abacavir [ABC]/lamivudine [3TC]; and compare partially blinded FTC/TDF to ABC/3TC (in combination with either RTV-enhanced ATV or EFV). 1800 treatment-nanve subjects will be enrolled and followed for 96 weeks after the last subject enrolls; they will be evaluated in a standardized fashion for efficacy, safety, and tolerability. There are 3 optional substudies, including a metabolic substudy (A5224s) that requires use of the GCRC for dual-energy x-ray absorptiometry (DEXA) scans. The metabolic substudy will evaluate the metabolic changes in 250 subjects (20 locally) assigned to the two different nucleoside reverse transcriptase inhibitor (NRTI) combinations given in A5202.

这个子项目是众多研究子项目之一